However, in another retrospective trial of combination immunotherapy conducted in 147 patients, PD-L1 expression (PD-L1 ≥ 1) was 63%, and the median TMB was lower in METex14-altered lung cancers than in unselected NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.